Literature DB >> 30108712

Identification of a potent kinase inhibitor targeting EML4-ALK fusion protein in non-small cell lung cancer.

Lian-Xiang Luo1, Ying Li1, Yu-Zhen Niu2, Yu-Wei Wang1, Qian-Qian Wang1, Xing-Xing Fan1, Jia-Hui Xu1, Liang Liu1, Elaine Lai-Han Leung1, Xiao-Jun Yao1,2.   

Abstract

ALK-fusion proteins play a fundamental role in the development of about 5% of non-small cell lung cancers. Herein, we identified the compound 5067-0952 as a potent ALK inhibitor, which inhibited cell growth, induced apoptosis, and suppressed the phosphorylation of ALK, subsequently blocking its downstream signaling pathway.

Entities:  

Year:  2017        PMID： 30108712      PMCID： PMC6071718          DOI： 10.1039/c7md00305f

Source DB:  PubMed          Journal:  Medchemcomm        ISSN： 2040-2503            Impact factor:   3.597


  18 in total

1.  Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.

Authors:  Ryohei Katayama; Alice T Shaw; Tahsin M Khan; Mari Mino-Kenudson; Benjamin J Solomon; Balazs Halmos; Nicholas A Jessop; John C Wain; Alan Tien Yeo; Cyril Benes; Lisa Drew; Jamal Carlos Saeh; Katherine Crosby; Lecia V Sequist; A John Iafrate; Jeffrey A Engelman
Journal:  Sci Transl Med       Date:  2012-01-25       Impact factor: 17.956

Review 2.  Molecular pathology of lung cancer: key to personalized medicine.

Authors:  Liang Cheng; Riley E Alexander; Gregory T Maclennan; Oscar W Cummings; Rodolfo Montironi; Antonio Lopez-Beltran; Harvey M Cramer; Darrell D Davidson; Shaobo Zhang
Journal:  Mod Pathol       Date:  2012-01-27       Impact factor: 7.842

Review 3.  New strategies for treatment of ALK-rearranged non-small cell lung cancers.

Authors:  Takaaki Sasaki; Pasi A Jänne
Journal:  Clin Cancer Res       Date:  2011-10-18       Impact factor: 12.531

4.  Crizotinib in ROS1-rearranged non-small-cell lung cancer.

Authors:  Alice T Shaw; Sai-Hong I Ou; Yung-Jue Bang; D Ross Camidge; Benjamin J Solomon; Ravi Salgia; Gregory J Riely; Marileila Varella-Garcia; Geoffrey I Shapiro; Daniel B Costa; Robert C Doebele; Long Phi Le; Zongli Zheng; Weiwei Tan; Patricia Stephenson; S Martin Shreeve; Lesley M Tye; James G Christensen; Keith D Wilner; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2014-09-27       Impact factor: 91.245

5.  Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Authors:  Solange Peters; D Ross Camidge; Alice T Shaw; Shirish Gadgeel; Jin S Ahn; Dong-Wan Kim; Sai-Hong I Ou; Maurice Pérol; Rafal Dziadziuszko; Rafael Rosell; Ali Zeaiter; Emmanuel Mitry; Sophie Golding; Bogdana Balas; Johannes Noe; Peter N Morcos; Tony Mok
Journal:  N Engl J Med       Date:  2017-06-06       Impact factor: 91.245

6.  Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.

Authors:  Scott N Gettinger; Lyudmila A Bazhenova; Corey J Langer; Ravi Salgia; Kathryn A Gold; Rafael Rosell; Alice T Shaw; Glen J Weiss; Meera Tugnait; Narayana I Narasimhan; David J Dorer; David Kerstein; Victor M Rivera; Timothy Clackson; Frank G Haluska; David Ross Camidge
Journal:  Lancet Oncol       Date:  2016-11-08       Impact factor: 41.316

7.  Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.

Authors:  Alice T Shaw; Tae Min Kim; Lucio Crinò; Cesare Gridelli; Katsuyuki Kiura; Geoffrey Liu; Silvia Novello; Alessandra Bearz; Oliver Gautschi; Tony Mok; Makoto Nishio; Giorgio Scagliotti; David R Spigel; Stéphanie Deudon; Cheng Zheng; Serafino Pantano; Patrick Urban; Cristian Massacesi; Kalyanee Viraswami-Appanna; Enriqueta Felip
Journal:  Lancet Oncol       Date:  2017-06-09       Impact factor: 41.316

8.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

9.  Escaping ALK inhibition: mechanisms of and strategies to overcome resistance.

Authors:  Christine M Lovly; William Pao
Journal:  Sci Transl Med       Date:  2012-02-08       Impact factor: 17.956

10.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.